Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zifcasiran · ADS-007

Oligonucleotide (siRNA) · Gene silencing: HIF2A (EPAS1)

Phase 1 Most advanced trial (none active)

What is Zifcasiran?

Zifcasiran is an siRNA that targets HIF2A mRNA to prevent production of hypoxia-inducible factor 2 alpha. It is being studied in clear cell renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADS-007, ARO-HIF2
Drug type: Oligonucleotide (siRNA)
Targets: HIF2A (EPAS1)
Mechanism: Gene silencing: HIF2A (EPAS1)
Pathways: tumor cell proliferation, tumor progression, metastasis
Therapy area: Oncology
In trials of: ARWR
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 5G6HL9K2G4

Conditions studied

Clear Cell Renal Cell Carcinoma

Other drugs acting on EPAS1

Belzutifan FDA approved Casdatifan Phase 1/2 Imdatifan Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z